Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865839 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00865839 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 32 participants.
The verdict
NCT00865839, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500 mg CLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 500 mg extended-release tablet) in healthy adult volunteers under fasting conditions.
Interventions
- DRUG Metformin HCl 500 mg tablets, single dose
- DRUG CLUCOPHAGE® XR 500 mg tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-03 |
| Est. Completion | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865839
The ClinicalTrials.gov registry entry for NCT00865839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin HCl 500 mg tablets, single dose is the first listed.
NCT00865839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865839 about?
NCT00865839 is a clinical study titled "A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500 mg CLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 500 mg extended-release tablet) i...
What is the current status of trial NCT00865839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2002-03. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00865839?
The interventions under investigation include: Metformin HCl 500 mg tablets, single dose (DRUG), CLUCOPHAGE® XR 500 mg tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00865839?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.